Form 4: MAIA Biotechnology Director Stan Smith Acquires Shares and Warrants

Director Stan Smith of MAIA Biotechnology, Inc. purchased 25,000 shares of common stock and 25,000 warrants on December 13, 2024.

Summary

• Stan Smith, a director at MAIA Biotechnology, Inc., acquired 25,000 shares of common stock at a price of $1.872 per share on December 13, 2024.
• The shares were purchased under the company's 2021 Equity Incentive Plan.
• Mr. Smith also acquired 25,000 warrants with an exercise price of $2.08, exercisable starting June 13, 2025, and expiring on June 13, 2030.
• These warrants were also issued under the 2021 Equity Incentive Plan.
• The transactions were made pursuant to a Securities Purchase Agreement.
• Following these transactions, Mr. Smith beneficially owns 1,130,060 shares of common stock indirectly through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by a company director. It is neither overwhelmingly positive nor negative, but rather a neutral event that provides transparency.

Positives

• A director's purchase of shares can be seen as a positive sign of confidence in the company's future.
• The acquisition of warrants suggests a long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors who are often granted stock options or warrants as part of their compensation or as an incentive to align their interests with shareholders.
• The purchase of shares and warrants by a director is a common occurrence and is not unusual in the biotech industry.

Stakeholder Impact

• The purchase of shares by a director may be viewed positively by shareholders, indicating confidence in the company's prospects.

Key Dates

Keywords

MAIA Biotechnology, Stan Smith, insider trading, Form 4, equity incentive plan, warrants, common stock, director, securities purchase agreement